ストックスクリーナーアプリを入手
4.14
4.39%
-0.19
前日終値:
$4.33
開ける：
$4.17
24時間の取引高:
31.14M
Relative Volume:
0.77
時価総額：
$1.77B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-2.671
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
-10.39%
1か月 パフォーマンス:
-29.71%
6か月 パフォーマンス:
-3.94%
1年 パフォーマンス:
-40.09%
1日の値動き範囲:
$4.13
$4.38
1週間の範囲:
$4.13
$4.96
52週間の値動き範囲:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.14 | 2.26B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Is Recursion Pharmaceuticals Inc. stock poised for growthCEO Change & Entry Point Strategy Guides - newser.com
Recursion Pharmaceuticals’ Revenue Miss Drives Stock Downward - StocksToTrade
RXRX Faces Setback as Revenue Misses Estimates - StocksToTrade
Recursion Pharmaceuticals’ Financial Struggles: What’s Next? - timothysykes.com
Recursion Pharmaceuticals Reports Q3 Revenue Fall Short of Expectations - timothysykes.com
Is it time to cut losses on Recursion Pharmaceuticals Inc.Inflation Watch & Verified Short-Term Trading Plans - newser.com
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Using Bollinger Bands to evaluate Recursion Pharmaceuticals Inc.Weekly Trading Summary & Risk Managed Investment Strategies - newser.com
Change at the top of Recursion as co-founder leaves CEO role - pharmaphorum
Has Recursion Pharmaceuticals Inc. formed a bullish divergenceWeekly Market Report & Safe Entry Trade Signal Reports - newser.com
Recursion Pharmaceuticals (RXRX): Assessing Valuation Following CEO Appointment and Disappointing Earnings Results - simplywall.st
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.Trend Reversal & Daily Stock Momentum Reports - newser.com
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - MSN
Will Recursion Pharmaceuticals Inc. stock maintain growth story2025 Valuation Update & Weekly High Return Opportunities - newser.com
A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion - Citeline News & Insights
How to interpret RSI for Recursion Pharmaceuticals Inc. stockWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Best Biotech Stocks To ConsiderNovember 6th - MarketBeat
Promising Biotech Stocks To ConsiderNovember 8th - MarketBeat
StockWatch: Recursion Slides on Data Update as New CEO Named - Genetic Engineering and Biotechnology News
Top Biotech Stocks To Follow NowNovember 5th - MarketBeat
Recursion Pharmaceuticals Hits Day Low at $4.60 Amid Price Pressure - Markets Mojo
Will Recursion’s (RXRX) CEO Transition and Roche Milestone Mark a Turning Point for Its AI Strategy? - simplywall.st
Recursion Pharmaceuticals Hits Day Low at $4.86 Amid Price Pressure - Markets Mojo
Recursion Pharmaceuticals Faces Steep Revenue Miss Amid Market Pressures - StocksToTrade
RXRX Revenue Miss Sparks Market Woes - timothysykes.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
RXRX Revenue Misses Q3 Expectations, Sparking Market Concerns - timothysykes.com
When is the best time to exit Recursion Pharmaceuticals Inc.Market Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Recursion refreshes leadership with CEO swap—Chutes & Ladders - Fierce Biotech
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q3 2025 Earnings Call Transcript - Insider Monkey
RXRX Faces Revenue Shortfall: Investor Panic? - timothysykes.com
Recursion outlines $800M cash runway through 2027 as leadership transition and partnership milestones drive next phase - MSN
Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Will RXRX Recover From Earnings Miss? - StocksToTrade
RXRX Earnings Miss: What You Need to Know - timothysykes.com
Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth - Yahoo Finance
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y - Yahoo Finance
RXRX Stock Price and Chart — NASDAQ:RXRX - TradingView
How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.07%
大文字化:
|
ボリューム (24 時間):